Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Pretomanid is used on drug resistant TB strains, sold by Viatris, now promoted into India via the Heal foundation and Bleepa and Carelocker.
https://en.wikipedia.org/wiki/Pretomanid
Europe https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela-previously-pretomanid-fgk
U.S.A. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461242/
India https://www.viatris.com/en-in/lm/India ( https://www.mylan.in/en/news/press-releases/2020/mylan-secures-dcgi-approval-in-india-for-pretomanid-a-treatment-for-highly-drug-resistant-forms-of-tuberculosis )
According to the report, India accounted for the highest global TB burden, with 27% of the 10.6 million people diagnosed with the disease in 2022. The country is also home to 47% of people who developed multi-drug resistant infection which is unresponsive or resistant to at least two of the first line of anti-TB drugs the same year.
Bleepa get paid to test everyone as they have to have a carelocker file set up, Viatris get to sell the cure to those affected.
This is take off time.
#FDBK
WHY are Viatris paying for Heal and Bleepa to test all of Indias 1.4B people?
Pretomanid
Viatris has launched pretomanid, specifically approved for adults with MDR-TB. It’s only the third new anti-TB drug approved in the past half-century.
THEY OWN THE CURE!
I read the RNS and had a head scratch about a charity funding this with donations for the whole of India, had a google search.
Heal is a charity, it is run by a Pharmaceutical giant called Viatris, tied in with the Indian Government to eradicate TB by 2025.
To do this they need fast, snappy communications from medical people to the Indian population to tell them clear or infected, they have an obvious weakness in communications and this is the area that Bleepa and care locker fill.
Viatris filed this ...
FY 2023 results:
‣ Total Revenues $15.4B
‣ Adjusted EBITDA $5.1B
‣ Free Cash Flow $2.4B
https://investor.viatris.com/static-files/4ba5a0bf-5ae4-4425-a697-233a95c6c763
Dr Dhara Shah, Head of Medical Affairs, Viatris India, said, “TB eradication in India is at a crucial juncture. The government is spearheading the TB elimination program to end TB by 2025. Via the India Fights TB initiative, we will provide accurate information to patients,
revenue growth
‣ FY 2023 results:
‣ Total Revenues $15.4B
‣ Adjusted EBITDA $5.1B
‣ Free Cash Flow $2.4B
https://investor.viatris.com/financial-and-filings/quarterly-results
Feeling more relaxed now a "charity" is going to support Bleepa in India.
Why is it still under a tenner?
These traders are insufferable !
Think I'll stick with the absolutely certain multibagger, ta.
Solid news with revenues, e.g. QVH (contract £1.6m), would help especially with India. That might be a few weeks away....
First sell will walk away with more profits and last to sell will walk away with less. Don't be greedy!
Sellers are done and new wave loading up.💯💪💪💪🚀🚀
Casp hasn't moved yet, news will be in a month or two was 2.4p last week, has production that just about covers costs, new shallow wells coming on line every 2 to 3 months.
Well worth spending a few hours researching the territory and reading old RNS
IMO Not a pump and dump.
Thanks for the tip /Recommend
I was buying as many as I could till it went NT then sat and waited ;)
Did the same with Casp...
Https://twitter.com/EquityTrader888/status/1759937160633844127?t=-0hFc9Kb62H9XebLjpKWXA&s=19
I was shouting from the roof top at 60p
technically bought at 58p and 60p
If you want a tip buy CASP, that RNS today is massive news, North Yelemes field deep wells 801,802 and 803 being put on international licence.
You weren't the only only buying these up at 60p ...
FDBK was a no brainer at 60p
tipped here and on Twitter
glad it's up again
got another one lined up......
MM's must be very offside on this.
Can't sell more than 99 shares before it goes NT : )
They've shut up shop to get everyone feeling locked in.
Not showing any trades either...
Yes, breakout inbound.💯💪🚀
NT to sell, NT to buy ... mad illiquid share at times.
Way under value now.Multi bags potential opportunity now.
Come on Tom,
explain the funding element in India, there's hints online that its $2 a head and if they test 275M people a year etc but needs this in writing to start multibagging.
So far all we've had is a Linkedin post and a damp squib of an RNS.
I think we're more akin to the picks & shovel suppliers of the gold (digital) rush.
Oops yes Dibs...silly me, anyway good luck it's certainly going in the right directions, always slice that spike though !
Davey - I take your points respectfully but would point out this is NOT a Bio/Pharma stock. It’s a diagnostics stock and they produce medical devices (which are in essence an App)
AGL is also a diagnostics stock that produces a medical device.
"sector on it's knees"
The point if FDBK is going through it's momentum stage mm's are pushing it. That can change, most Bio/Pharma are struggling badly but if the mm's manipulated any of them up 50% all of a sudden everybody wants to buy in.
Agl indeed has a lot to prove just like all the other Bio's, just takes one RNS to change them but sector is on it's news but a couple of big % winners today so far
Davey - ‘value’ does not come into it here it’s all about potential for huge growth. And I know which stock I’d prefer to own between this and AGL. I know ALL about that company and its lifestyle leader.